Reply to Kojima and Klausner

Jean B Nachega^{1

2

3}, Nadia A Sam-Agudu^{4

5

6}, Lynne M Mofenson⁷, Mauro Schechter⁸, John W Mellors⁹

Affiliations

¹ Department of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania.
² Department of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Faculty of Medicine and Health Sciences, Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa.
⁴ Institute of Human Virology, University of Maryland School of Medicine, Baltimore.
⁵ International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja.
⁶ Department of Paediatrics, University of Cape Coast School of Medical Sciences, Ghana.
⁷ Elizabeth Glaser Pediatric AIDS Foundation, Washington, D.C.
⁸ Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil.
⁹ Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pennyslvania.

Comment

Jean B Nachega et al. Clin Infect Dis. 2018.

. 2018 Oct 15;67(9):1469-1470.

doi: 10.1093/cid/ciy345.

Jean B Nachega^{1

2

3}, Nadia A Sam-Agudu^{4

5

6}, Lynne M Mofenson⁷, Mauro Schechter⁸, John W Mellors⁹

¹ Department of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania.
² Department of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
³ Faculty of Medicine and Health Sciences, Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa.
⁴ Institute of Human Virology, University of Maryland School of Medicine, Baltimore.
⁵ International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja.
⁶ Department of Paediatrics, University of Cape Coast School of Medical Sciences, Ghana.
⁷ Elizabeth Glaser Pediatric AIDS Foundation, Washington, D.C.
⁸ Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil.
⁹ Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pennyslvania.

No abstract available

Comment on

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities.
Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Nachega JB, et al. Clin Infect Dis. 2018 May 2;66(10):1487-1491. doi: 10.1093/cid/ciy008. Clin Infect Dis. 2018. PMID: 29324994 Free PMC article.
Strategies to Increase Human Immunodeficiency Virus Testing Among Men to Reach UNAIDS 90-90-90 Targets.
Kojima N, Klausner JD. Kojima N, et al. Clin Infect Dis. 2018 Oct 15;67(9):1468-1469. doi: 10.1093/cid/ciy344. Clin Infect Dis. 2018. PMID: 29718167 Free PMC article. No abstract available.

1. Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with HIV on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities. Clin Infect Dis 2018; 66:1487–1491. - PMC - PubMed
1. Kojima N, Klausner JD. Strategies to increase human immunodeficiency virus testing among men to reach UNAIDS 90-90-90 target. Clin Infect Dis 2018; 67:1468–9. - PMC - PubMed